Previous 10 | Next 10 |
Healthcare Executive and Strategy Consultant Brings Considerable Innovation, Commercialization and Entrepreneurial Expertise Athersys, Inc. (Nasdaq: ATHX), a regenerative medicine company developing MultiStem ® (invimestrocel) for critical care indications, announced today the ...
2023-08-06 04:08:12 ET Summary DiaMedica Therapeutics is a clinical-stage biopharmaceutical company focused on developing recombinant proteins to treat life-threatening diseases. Its main clinical candidate, DM199, is undergoing evaluation in a Phase 2/3 study for the treatment of...
2023-08-04 15:00:42 ET Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week, or the Seeking Alpha earnings calendar ...
Athersys, Inc. (NASDAQ: ATHX) , a cell therapy and regenerative medicine company developing MultiStem ® (invimestrocel) for critical care indications, announced today it will host a business update conference call on August 9, 2023, at 4:30 p.m. Eastern Time. Dan Camardo, Chief Executi...
Athersys, Inc. (NASDAQ: ATHX), a regenerative medicine company developing MultiStem ® (invimestrocel) cell therapy for critical care indications, announces patient enrollment has begun in the third and final cohort in MATRICS-1, the Phase 2 clinical study evaluating MultiStem ® ...
2023-05-23 10:23:06 ET Athersys ( NASDAQ: ATHX ) has restructured its outstanding debt with a supplier, involving an $11.8M payment plan and a $15M convertible note. The new agreement includes monthly cash payments of $250,000 starting from October 2023 and a convertible note ...
Athersys, Inc. (NASDAQ: ATHX), a regenerative medicine company developing MultiStem ® (invimestrocel) cell therapy for critical care indications announced it has restructured its outstanding debt with a supplier (“the supplier”). The Company previously entered into agreem...
2023-05-18 12:14:02 ET Athersys press release ( NASDAQ: ATHX ): Q1 GAAP EPS of -$0.43 misses by $0.14 . Cash and cash equivalents were $3.1 million as of March 31, 2023 compared with $9.0 million as of December 31, 2022. For further details see: Athersys ...
Athersys, Inc. (NASDAQ: ATHX), a regenerative medicine company developing MultiStem ® (invimestrocel) cell therapy for critical care indications, announced on Monday, May 15 th financial results for the three months ended March 31, 2023 and provided a business update. First Q...
Athersys, Inc. (NASDAQ: ATHX), a regenerative medicine company developing MultiStem ® (invimestrocel) cell therapy for critical care indications, announced today its participation in three upcoming conferences during the month of May. Chris Temple, Vice President of Operations, will be p...
News, Short Squeeze, Breakout and More Instantly...
Athersys, Inc. (OTC: ATHX), a regenerative medicine company developing MultiStem ® (invimestrocel) cell therapy for critical care indications, announced financial results for the three and nine months ended September 30, 2023 and provided a business update. Third Quarter 2023 and...
INVO BioScience Inc. (INVO) is expected to report for Q3 2023 HIVE Blockchain Technologies Ltd (HIVE) is expected to report $-0.13 for Q2 2024 BioNexus Gene Lab Corp (BGLC) is expected to report for Q1 2024 Adhera Therapeutics Inc (ATRX) is expected to report for Q1 2024 Altus Pow...
Gainers SciSparc Ltd. (NASDAQ: SPRC) shares climbed 146.2% to $6.97. Aegis Capital Corp. acted as exclusive placement agent on a $5.0 million pri...